Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma

  • End date
    Jul 30, 2024
  • participants needed
  • sponsor
    Tang-Du Hospital
Updated on 26 January 2021
serum pregnancy test
measurable disease
direct bilirubin
neutrophil count
chemotherapy regimen
solid tumors
thymic carcinoma
thymic neoplasm


This is an investigational, single arm study.


Pembrolizumab is FDA approved and commercially available for treatment of many types of cancers. It is considered investigational to use chemotherapy combined with pembrolizumab to treat thymoma or Thymic carcinoma.

Subjects will be evaluated for eligibility during a 28-day screening period. Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1).

Up to 40 participants will be enrolled in this study.

Condition Thymoma, Thymoma, Thymomas, thymic carcinoma
Treatment Chemotherapy+Pembrolizumab.
Clinical Study IdentifierNCT04554524
SponsorTang-Du Hospital
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Have a histologically or cytologically confirmed diagnosis of unresectable thymoma or thymic carcinoma
Have measurable disease based on RECIST 1.1
Patients must not have had prior systemic anti-cancer therapy for locally advanced or metastatic unresectable thymoma or thymic carcinoma
Patients who could provision of archival to evaluate the PD-L1 expression status
Be 18 years of age on day of signing informed consent
Life expectancy > 3 months
Have a performance status (PS) of 0 or 1 on the ECOG PS
Demonstrate adequate organ function as defined below all screening labs should be performed
Hematological: absolute neutrophil count 1500/mcL; platelets 80000mcL; hemoglobin 9g/dL or 5.6 mmol/L without transfusion within 4 weeks
Renal: serum creatinine OR measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) 1.5 X upper limit of normal (ULN) OR 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
Hepatic: serum total bilirubin 1.5 X ULN OR direct bilirubin ULN for subjects with total bilirubin levels > 1.5 ULN; AST (SGOT) and ALT (SGPT) 2.5 X ULN OR 5 X ULN for subjects with liver metastases; albumin 2.5mg/dL
Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Female subject of childbearing potential should have a negative urine or serum pregnancy. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Exclusion Criteria

Patients have had prior systemic anti-cancer therapy
Has a known additional malignancy past 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 3 days prior to trial treatment
Hypersensitivity to carboplatin or paclitaxel or nab-paclitaxel or any of their excipients
Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
Asthmatic subjects requiring intermittent use of bronchodilators, inhaled steroids or local steroid injections were not excluded
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. Participated in any other pembrolizumab trials or was treated with pembrolizumab
Has an active infection requiring systemic therapy
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
As known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note